KEEPING AN OPEN MIND ON LONG-TERM USE OF PROTON PUMP INHIBITORS

Authors

  • C STANCIU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Anca TRIFAN “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Abstract

Since the release of omeprazole, the first proton pump inhibitor (PPI), in 1988 in Europe and, two years later, in the Unit-ed States, six other PPIs have become available such as pantoprazole, esomepra-zole, lansoprazole, dexlansoprazole, and rabeprazole. The discovery of omeprazole is the story of a huge therapeutic success, the result of over 20 years of hard work and meticulous research made by an extraordi-nary team of more than 150 researchers, who discovered and tested over 800 com-pounds, surmounting unimaginable obsta-cles.

References

1. Brunner G, Athman C, Schneider A. Long-term, open label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther 2012; 36: 37-47.
2. Targownik L, Luo Y, Goertzen A, et al. Comparing bone structure and bone metabolism between long-term proton pump inhibitor users and non-users. Gastroenterology 2015; 148: S-153.
3. Othman F, Crooks CJ, Card TR. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. BMJ 2016; 355: i5813.
4. Shah NH, LePendu P, Bauer-Mehren A, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. Plos One 2015; 10: e0124653.
5. Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Risk of death among users of proton pump inhibitor: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017; 7: e015735.
6. Savarino V, Dulbecco P, Savarino E. Are proton pump inhibitors really so dangerous? Digestive and Liver Disease 2016; 48: 851-859.
7. Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroen-terology 2017; 152: 706-715.
8. Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterol-ogy 2017; 153: 35-48.
9. Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney dis-ease. JAMA Intern Med 2016; 176: 238-246.
10. Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesia: a systematic review and meta-analysis of observational studies. Ren Fail 2015; 37: 1237-1241.
11. Trifan A, Stanciu C, Girleanu I, et al. Proton pump inhibitor therapy and risk of Clostridium difficile infection: systematic review and meta-analysis. In press.
12. Tleyjeh IM, Bin Abdulhak AA, Riaz M, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection: a contemporary systematic review and meta-analysis. Plos One 2012; 7: e50836.
13. Tsai CF, Chen MH, Wang YP, et al. Proton pump inhibitor increased risk for hepatic encephalopathy in patients with cirrhosis in a population study. Gastroenterology 2017; 152: 134-141.
14. Xu HB, Wang HD, Li CH, et al. Proton pump use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. Genet Mol Res 2015; 14: 7490-7501.
15. Haenisch B, von Holt K, Wiese B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Nerosci 2015; 265: 419-428.
16. Gomm W, von Holt K, Thome P, et al. Association of proton pump inhibitors with risk of dementia: a phamacoepidemiological claims data analysis. JAMA Neurol 2016; 73: 410-416.
17. Badiola N, Alcalde V, Pujol a, et al. The proton pump inhibitor lansoprazole enhances amyloid beta production. Plos One 2013; 8: e55837.
18. Wang YF, Chen YT, Luo JC, Chen TJ, Wu JC, Wang SJ. Proton-Pump inhibitor use and the risk of first-time ischemic stroke in the general population: a nationwide population-based study. Am J Gas-troenterol 2017; 112: 1084-1093.
19. Dunn SP, Steinhub SR, Bauer D, Charnigo RJ, Berger PB, Topol EJ. Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials. J Am Heart Assoc 2013; 2(1): p. e004564.
20. Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev 2014;12:CD010623.
21. Zelter A, Fernandez JL, Bilder C, et al. Fundic gland polyps and association with proton pump inhibi-tor intake: a prospective study in 1,780 endoscopies. Dig Dis Sci 2011; 56: 1743-1748.

Additional Files

Published

2017-09-30